ATE404188T1 - Verfahren und zusammensetzungen zur behandlung von augenerkrankungen mit retinyl-derivaten - Google Patents

Verfahren und zusammensetzungen zur behandlung von augenerkrankungen mit retinyl-derivaten

Info

Publication number
ATE404188T1
ATE404188T1 AT05758777T AT05758777T ATE404188T1 AT E404188 T1 ATE404188 T1 AT E404188T1 AT 05758777 T AT05758777 T AT 05758777T AT 05758777 T AT05758777 T AT 05758777T AT E404188 T1 ATE404188 T1 AT E404188T1
Authority
AT
Austria
Prior art keywords
compositions
methods
eye diseases
treating eye
retinyl derivatives
Prior art date
Application number
AT05758777T
Other languages
German (de)
English (en)
Inventor
Kenneth Widder
Jay Lichter
Nathan L Mata
Original Assignee
Sirion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34981643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE404188(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sirion Therapeutics Inc filed Critical Sirion Therapeutics Inc
Application granted granted Critical
Publication of ATE404188T1 publication Critical patent/ATE404188T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05758777T 2004-06-23 2005-06-06 Verfahren und zusammensetzungen zur behandlung von augenerkrankungen mit retinyl-derivaten ATE404188T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58229304P 2004-06-23 2004-06-23
US62969504P 2004-11-19 2004-11-19
US66090405P 2005-03-11 2005-03-11
US67240505P 2005-04-18 2005-04-18

Publications (1)

Publication Number Publication Date
ATE404188T1 true ATE404188T1 (de) 2008-08-15

Family

ID=34981643

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05758777T ATE404188T1 (de) 2004-06-23 2005-06-06 Verfahren und zusammensetzungen zur behandlung von augenerkrankungen mit retinyl-derivaten

Country Status (26)

Country Link
US (3) US8314152B2 (enExample)
EP (3) EP2277516A1 (enExample)
JP (1) JP4855396B2 (enExample)
KR (1) KR100862930B1 (enExample)
AR (1) AR049929A1 (enExample)
AT (1) ATE404188T1 (enExample)
AU (1) AU2005262558B8 (enExample)
BR (1) BRPI0512569A (enExample)
CA (1) CA2569691C (enExample)
CY (1) CY1110435T1 (enExample)
DE (1) DE602005008970D1 (enExample)
DK (1) DK1768657T3 (enExample)
EA (1) EA011864B1 (enExample)
ES (1) ES2313368T3 (enExample)
GE (1) GEP20084520B (enExample)
IL (1) IL179872A (enExample)
LV (1) LV13564B (enExample)
MX (1) MXPA06014978A (enExample)
NO (1) NO20070408L (enExample)
NZ (1) NZ551955A (enExample)
PL (1) PL1768657T3 (enExample)
PT (1) PT1768657E (enExample)
SG (1) SG140607A1 (enExample)
SI (1) SI1768657T1 (enExample)
TW (1) TWI396532B (enExample)
WO (1) WO2006007314A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2327401A3 (en) 2003-03-14 2011-10-19 University of Washington Retinoid Replacements and Opsin Agonists and Methods for the Use Thereof
AU2005215778B2 (en) 2004-02-17 2009-03-12 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
JP2007525496A (ja) * 2004-02-17 2007-09-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 黄班変性症を含む眼科疾患の管理
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
JP5166026B2 (ja) 2004-06-18 2013-03-21 ユニバーシティ オブ ワシントン 視力障害の治療のためのレチナール誘導体およびその使用方法
DK1768657T3 (da) 2004-06-23 2008-12-01 Sirion Therapeutics Inc Fremgangsmåder og sammensætninger til at behandle ophthalmiske tilstande med retinylderivater
US20060089411A1 (en) * 2004-08-07 2006-04-27 Gierhart Dennis L Treatment of Stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin
WO2006033734A2 (en) * 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
EP1804771A2 (en) * 2004-10-28 2007-07-11 Idexx Laboratories, Inc. Compositions for controlled delivery of pharmaceutically active compounds
WO2006052860A2 (en) * 2004-11-04 2006-05-18 Sirion Therapeutics, Inc. Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation
SG144145A1 (en) * 2004-12-08 2008-07-29 Sirion Therapeutics Inc Methods, assays and compositions for treating retinol-related diseases
UA81382C2 (en) * 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding
US7754679B2 (en) * 2005-11-16 2010-07-13 Idexx Laboratories, Inc. Pharmaceutical compositions for the administration of aptamers
US8114440B2 (en) * 2005-11-16 2012-02-14 Idexx Laboratories Inc. Pharmaceutical compositions for the administration of aptamers
WO2007150046A2 (en) * 2006-06-22 2007-12-27 Sirion Therapeutics, Inc Methods and compositions for treating ophthalmic conditions via modulation of megalin activity
EP2069391A4 (en) * 2006-07-27 2009-12-30 Univ Florida COMPOSITIONS AND METHODS FOR TREATING AND / OR PREVENTING OPHTHALMOLOGICAL DISEASES
EP2069390A4 (en) * 2006-07-27 2009-12-30 Univ Florida OPSIN STABILIZING COMPOUNDS AND METHODS OF USE
CA2657164A1 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Compositions and methods for treating or preventing ophthalmic light toxicity
US8828960B2 (en) * 2007-07-17 2014-09-09 Idexx Laboratories, Inc. Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds
JP6022746B2 (ja) 2008-02-11 2016-11-09 ユニヴァーシティ オブ ワシントン 加齢関連性網膜機能不全の治療及び予防方法
WO2009114136A2 (en) * 2008-03-12 2009-09-17 Albert Einstein College Of Medicine Of Yeshiva University Fenretinide derivatives and uses thereof as therapeutic, diagnostic and imaging agents
MX2011000545A (es) * 2008-07-14 2011-02-24 Otonomy Inc Composiciones de liberacion controlada para la modulacion de apoptosis y metodos para el tratamiento de trastornos oticos.
EP2427052B1 (en) * 2009-05-04 2015-08-26 Acucela, Inc. Compositions for use in the treatment of glaucoma or ocular hypertension
IN2012DN00352A (enExample) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
JP5663025B2 (ja) 2009-09-15 2015-02-04 キューエルティー インコーポレイテッド ９−ｃｉｓ−レチニルエステルを脂質ビヒクル中に含む医薬製剤
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
CA2796991A1 (en) * 2010-04-19 2011-10-27 Qlt Inc. Therapeutic regimen and methods for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency
EP2944628B1 (en) 2011-11-30 2017-01-04 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
WO2013119988A1 (en) * 2012-02-10 2013-08-15 Taiwan Liposome Company, Ltd Pharmaceutical compositions to reduce complications of ocular steroid
MX370928B (es) 2012-03-01 2020-01-08 Retinagenix LLC El uso de 9-cis-retinil acetato para mejorar la función visual de un sujeto que padece de pérdida de la función visual originada por una deficiencia retinoide endógena de 11-cis retinal.
WO2014003850A2 (en) 2012-06-26 2014-01-03 Timothy Paul Foster Methods for treatment of ocular diseases
US9011845B2 (en) 2012-06-26 2015-04-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for treatment of inflammatory and infectious viral diseases
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US10092393B2 (en) 2013-03-14 2018-10-09 Allotex, Inc. Corneal implant systems and methods
US10471118B2 (en) * 2014-05-30 2019-11-12 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
ES2848999T3 (es) 2014-10-24 2021-08-13 Takeda Pharmaceuticals Co Compuestos heteroarilo para el tratamiento de enfermedades oftálmicas
EP3233174B1 (en) * 2014-12-19 2021-03-31 Kemin Industries, Inc. Intraocular delivery of bioactive molecules using iontophoresis
US10449090B2 (en) 2015-07-31 2019-10-22 Allotex, Inc. Corneal implant systems and methods
RU2718065C2 (ru) * 2016-02-15 2020-03-30 Кемин Индастриз, Инк. Положительно заряженные липосомы в качестве липофильных молекул-носителей
US11395853B2 (en) 2016-06-23 2022-07-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions
US11369695B2 (en) 2016-12-05 2022-06-28 The Jackson Laboratory Fat droplets in retina and optic nerve as a diagnostic marker for neurodegeneration and glaucoma in humans
EP3650045B1 (en) * 2017-07-04 2024-11-13 Daiichi Sankyo Company, Limited Drug for retinal degenerative disease associated with photoreceptor degeneration
US20220211654A1 (en) * 2019-05-06 2022-07-07 The Regents Of The University Of California Materials and methods for treating age-related macular degeneration
FR3105790B1 (fr) * 2019-12-26 2022-01-14 Biophytis Composés chimiques ciblant l’œil et leur utilisation dans le traitement de maladies oculaires

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190594A (en) 1975-11-03 1980-02-26 Johnson & Johnson Retinoic acid derivatives
US4323581A (en) 1978-07-31 1982-04-06 Johnson & Johnson Method of treating carcinogenesis
US4665098A (en) 1985-03-28 1987-05-12 Mcneilab, Inc. Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability
US4874795A (en) 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
US4673044A (en) * 1985-08-02 1987-06-16 Eastman Christensen Co. Earth boring bit for soft to hard formations
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4682663A (en) * 1986-02-18 1987-07-28 Reed Tool Company Mounting means for cutting elements in drag type rotary drill bit
US4743400A (en) 1986-09-22 1988-05-10 Mcneilab, Inc. Process for preparing retinoyl chlorides
WO1991001745A1 (en) 1989-07-28 1991-02-21 Sloan-Kettering Institute For Cancer Research Growth factors containing vitamin a or other retinoids and uses thereof
US5814612A (en) 1991-04-09 1998-09-29 Sloan-Kettering Institute For Cancer Research Retinol derivatives and uses thereof
US6506917B1 (en) 1991-12-18 2003-01-14 The Salk Institute For Biological Studies Compounds and compositions useful for modulation of processes mediated by RXR
US6050354A (en) * 1992-01-31 2000-04-18 Baker Hughes Incorporated Rolling cutter bit with shear cutting gage
US5314909A (en) 1993-03-17 1994-05-24 Merck & Co., Inc. Use of non-steroidal antiiflammatory agents in macular degeneration
US5399757A (en) 1993-07-20 1995-03-21 Ortho Pharmaceutical Corporation Process for the preparation of N-(4-hydroxyphenyl)-retinamide
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5596011A (en) 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
US5702357A (en) * 1995-06-07 1997-12-30 Cobe Laboratories, Inc. Extracorporeal blood processing methods and apparatus
US5706906A (en) * 1996-02-15 1998-01-13 Baker Hughes Incorporated Superabrasive cutting element with enhanced durability and increased wear life, and apparatus so equipped
US5758733A (en) * 1996-04-17 1998-06-02 Baker Hughes Incorporated Earth-boring bit with super-hard cutting elements
US5846220A (en) 1996-04-30 1998-12-08 Medtronic, Inc. Therapeutic method for treatment of Alzheimer's disease
US6034211A (en) 1996-06-03 2000-03-07 Kelly; Jeffery W. β-sheet nucleating peptidomimetics
GB9621217D0 (en) * 1996-10-11 1996-11-27 Camco Drilling Group Ltd Improvements in or relating to preform cutting elements for rotary drill bits
AU5727798A (en) 1996-12-23 1998-07-17 Texas A & M University, The Anti-amyloidogenic agents
US5955305A (en) 1997-04-28 1999-09-21 Incyte Pharmaceuticals, Inc. Human retinoid binding protein
US5776915A (en) 1997-08-12 1998-07-07 Clarion Pharmaceuticals Inc. Phosphocholines of retinoids
ATE411016T1 (de) 1997-08-15 2008-10-15 Univ Duke Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
CA2331620A1 (en) 1998-05-11 1999-11-18 The Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
EP1216221A2 (en) 1999-09-14 2002-06-26 Ligand Pharmaceuticals Incorporated Rxr modulators with improved pharmacologic profile
AU3082901A (en) 1999-11-23 2001-06-04 Gerhart Graupner Modulation of signal transduction
US20020031539A1 (en) 2000-08-30 2002-03-14 The Brigham And Women's Hospital, Inc. Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma
EP1328262A2 (en) 2000-10-17 2003-07-23 Board of Regents, The University of Texas System A method to incorporate n-(4-hydroxyphenyl) retinamide in liposomes
US6408958B1 (en) * 2000-10-23 2002-06-25 Baker Hughes Incorporated Superabrasive cutting assemblies including cutters of varying orientations and drill bits so equipped
WO2002058689A1 (en) 2000-12-05 2002-08-01 Childrens Hospital Los Angeles Pharmaceutical compositions of fenretinide having increased bioavailability and methods of using the same
US20030032078A1 (en) 2001-01-23 2003-02-13 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of macular and retinal degenerations
EP1390343B1 (en) 2001-05-29 2009-10-14 Chebigen Co., Ltd. Novel retinoid derivatives and an anti-cancer pharmaceutical composition comprising said compounds
CA2450562A1 (en) 2001-06-22 2003-01-03 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2002316593A1 (en) 2001-07-06 2003-01-21 The Ohio State University Research Foundation Solid phase synthesis of arylretinamides
US6599891B2 (en) 2001-07-20 2003-07-29 Qlt Inc. Treatment of macular edema
US20030229062A1 (en) 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
US20040014131A1 (en) 2002-07-09 2004-01-22 Pfizer Inc. Assay methods
US7595430B2 (en) 2002-10-30 2009-09-29 University Of Kentucky Research Foundation Methods and animal model for analyzing age-related macular degeneration
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
WO2004050101A2 (en) 2002-11-29 2004-06-17 Gpc Biotech Ag Formulations useful against hepatitis c virus infections
SI21392A (sl) 2002-12-24 2004-06-30 Vinko Kunc Postopek za avtomatsko nastavitev ojačenja izpraševalnikovega sprejemnika v brezkontaktnem identifikacijskem sistemu
WO2004069203A2 (en) 2003-01-31 2004-08-19 Childrens Hospital Los Angeles Research Institute Oral compositions of fenretinide having increased bioavailability and methods of using the same
FI20030426A7 (fi) 2003-03-24 2004-09-25 Jaervinen Tomi Syklodekstriinikompleksit
US7178609B2 (en) * 2003-08-19 2007-02-20 Baker Hughes Incorporated Window mill and drill bit
JP4869942B2 (ja) 2003-12-11 2012-02-08 ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド インスリン感受性／抵抗性、糖尿病および肥満におけるｒｂｐ４
WO2005077176A1 (en) 2004-02-11 2005-08-25 The Trustees Of Columbia University In The City Of New York Anthocyanin compounds and methods of use thereof
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
AU2005215778B2 (en) * 2004-02-17 2009-03-12 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
CA2601278C (en) 2004-03-17 2014-06-10 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
JP5166026B2 (ja) 2004-06-18 2013-03-21 ユニバーシティ オブ ワシントン 視力障害の治療のためのレチナール誘導体およびその使用方法
DK1768657T3 (da) 2004-06-23 2008-12-01 Sirion Therapeutics Inc Fremgangsmåder og sammensætninger til at behandle ophthalmiske tilstande med retinylderivater
US7286860B2 (en) 2004-07-23 2007-10-23 Dyna Llc Systems and methods for a comfortable wireless communication device
WO2006033734A2 (en) 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
WO2006052860A2 (en) 2004-11-04 2006-05-18 Sirion Therapeutics, Inc. Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation
SG144145A1 (en) 2004-12-08 2008-07-29 Sirion Therapeutics Inc Methods, assays and compositions for treating retinol-related diseases
UA81382C2 (en) 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding

Also Published As

Publication number Publication date
KR100862930B1 (ko) 2008-10-13
AU2005262558B2 (en) 2008-03-20
EP2277516A1 (en) 2011-01-26
AU2005262558B8 (en) 2008-04-10
MXPA06014978A (es) 2007-04-25
KR20070074541A (ko) 2007-07-12
AR049929A1 (es) 2006-09-13
EA200700109A1 (ru) 2007-10-26
US20110294891A1 (en) 2011-12-01
NO20070408L (no) 2007-03-20
EP2025336A1 (en) 2009-02-18
GEP20084520B (en) 2008-10-27
SI1768657T1 (sl) 2009-02-28
JP2008504257A (ja) 2008-02-14
US20060167088A1 (en) 2006-07-27
IL179872A (en) 2013-01-31
TWI396532B (zh) 2013-05-21
US8314152B2 (en) 2012-11-20
CA2569691A1 (en) 2006-01-19
CA2569691C (en) 2010-08-17
PT1768657E (pt) 2008-11-25
CY1110435T1 (el) 2015-04-29
SG140607A1 (en) 2008-03-28
ES2313368T3 (es) 2009-03-01
BRPI0512569A (pt) 2008-03-25
EP1768657A1 (en) 2007-04-04
AU2005262558A1 (en) 2006-01-19
US20100298443A1 (en) 2010-11-25
NZ551955A (en) 2010-08-27
PL1768657T3 (pl) 2009-01-30
US8410168B2 (en) 2013-04-02
DK1768657T3 (da) 2008-12-01
TW200612891A (en) 2006-05-01
WO2006007314A1 (en) 2006-01-19
IL179872A0 (en) 2007-05-15
EA011864B1 (ru) 2009-06-30
EP1768657B1 (en) 2008-08-13
LV13564B (en) 2008-02-20
HK1107671A1 (en) 2008-04-11
JP4855396B2 (ja) 2012-01-18
DE602005008970D1 (de) 2008-09-25

Similar Documents

Publication Publication Date Title
ATE404188T1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen mit retinyl-derivaten
EP1881823A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS
ATE489955T1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
EP1896083A4 (en) METHOD FOR TREATING PUMP DISEASE USING 1-DEOXYNOJIRIMYCIN AND ITS DERIVATIVES
DE602004021790D1 (de) Verfahren zur behandlung von parkinson-krankheit
EP2141989A4 (en) Compositions and methods for prophylaxis and treatment of addictions
EP1626730A4 (en) METHOD, DEVICE AND COMPOSITION FOR TREATING ACNE
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
EP2219669A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOIMMUNE AND ALLERGIC DISEASES
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
EP1732484A4 (en) OPHTHALMIC IMPLANT FOR THE TREATMENT OF GLAUCOMA
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
EP2049140A4 (en) BOX AND METHODS FOR TREATING AN INTERVERTEBRAL DISC
EP2046366A4 (en) METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION
EP2069391A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND / OR PREVENTING OPHTHALMOLOGICAL DISEASES
EP2124991A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING DYSERENCE
EP2037736A4 (en) METHODS OF TREATING RENAL KYSTIC DISEASES
EP1948675A4 (en) METHODS AND COMPOSITIONS FOR TREATING MARFAN SYNDROME AND RELATED DISORDERS
EP1635801A4 (en) METHODS OF TREATMENT AND PREVENTION OF CARDIAC ARRHYTHMIA
ATE328880T1 (de) Tetrazolderivate und verfahren zur behandlung von stoffwechselbedingten erkrankungen damit
ATE415163T1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
ATE463246T1 (de) Formulierung und verfahren zur behandlung von thrombocythämie
DE60327856D1 (de) Zusammensetzungen und verfahren zur hautbräunung
ATE374799T1 (de) Verfahren zur behandlung von pigmenten in partikulärer form
EP1888106A4 (en) COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH EPRININ SIGNALING USING CUPREDOXINS

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1768657

Country of ref document: EP

EEIH Change in the person of patent owner